These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 35401164)

  • 1. Advances and Challenges in Intranasal Delivery of Antipsychotic Agents Targeting the Central Nervous System.
    Pandey M; Jain N; Kanoujia J; Hussain Z; Gorain B
    Front Pharmacol; 2022; 13():865590. PubMed ID: 35401164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies.
    Goel H; Kalra V; Verma SK; Dubey SK; Tiwary AK
    J Control Release; 2022 Jan; 341():782-811. PubMed ID: 34906605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal Drug Delivery: A Non-Invasive Approach for the Better Delivery of Neurotherapeutics.
    Kumar H; Mishra G; Sharma AK; Gothwal A; Kesharwani P; Gupta U
    Pharm Nanotechnol; 2017; 5(3):203-214. PubMed ID: 28521670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-depth Mechanism, Challenges, and Opportunities of Delivering Therapeutics in Brain Using Intranasal Route.
    Ghosh A; Majie A; Karmakar V; Chatterjee K; Chakraborty S; Pandey M; Jain N; Roy Sarkar S; Nair AB; Gorain B
    AAPS PharmSciTech; 2024 May; 25(5):96. PubMed ID: 38710855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Versatile Nanoparticulate Systems as a Prosperous Platform for Targeted Nose-Brain Drug Delivery.
    Taha E; Shetta A; Nour SA; Naguib MJ; Mamdouh W
    Mol Pharm; 2024 Mar; 21(3):999-1014. PubMed ID: 38329097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal delivery: circumventing the iron curtain to treat neurological disorders.
    Jiang Y; Li Y; Liu X
    Expert Opin Drug Deliv; 2015; 12(11):1717-25. PubMed ID: 26206202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease.
    Arora D; Bhatt S; Kumar M; Vattikonda HDC; Taneja Y; Jain V; Joshi V; Gali CC
    Curr Pharm Des; 2020; 26(27):3281-3299. PubMed ID: 32228421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS.
    Hanson LR; Frey WH
    J Neuroimmune Pharmacol; 2007 Mar; 2(1):81-6. PubMed ID: 18040829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in brain targeting drug delivery system by nasal route.
    Khan AR; Liu M; Khan MW; Zhai G
    J Control Release; 2017 Dec; 268():364-389. PubMed ID: 28887135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nasal delivery of neurotherapeutics
    Rajput A; Pingale P; Dhapte-Pawar V
    Front Pharmacol; 2022; 13():979682. PubMed ID: 36176429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal Formulations for Nose-to-Brain Delivery: Recent Advances and Future Perspectives.
    Hong SS; Oh KT; Choi HG; Lim SJ
    Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31627301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal nanoparticulate delivery systems for neurodegenerative disorders: a review.
    Babu SR; Shekara HH; Sahoo AK; Harsha Vardhan PV; Thiruppathi N; Venkatesh MP
    Ther Deliv; 2023 Sep; 14(9):571-594. PubMed ID: 37691577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Patent Review on Nanotechnology-Based Nose-to-Brain Drug Delivery.
    Singh R; Brumlik C; Vaidya M; Choudhury A
    Recent Pat Nanotechnol; 2020; 14(3):174-192. PubMed ID: 32384043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases.
    Fan Y; Chen M; Zhang J; Maincent P; Xia X; Wu W
    Crit Rev Ther Drug Carrier Syst; 2018; 35(5):433-467. PubMed ID: 30317945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation, characterization, and optimization of asenapine maleate mucoadhesive nanoemulsion using Box-Behnken design: In vitro and in vivo studies for brain targeting.
    Kumbhar SA; Kokare CR; Shrivastava B; Gorain B; Choudhury H
    Int J Pharm; 2020 Aug; 586():119499. PubMed ID: 32505580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal Delivery of Functionalized Polymeric Nanomaterials to the Brain.
    Zha S; Wong KL; All AH
    Adv Healthc Mater; 2022 Jun; 11(11):e2102610. PubMed ID: 35166052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal delivery of mitochondria targeted neuroprotective compounds for traumatic brain injury: screening based on pharmacological and physiological properties.
    Pandya JD; Musyaju S; Modi HR; Okada-Rising SL; Bailey ZS; Scultetus AH; Shear DA
    J Transl Med; 2024 Feb; 22(1):167. PubMed ID: 38365798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.
    Hanson LR; Frey WH
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S5. PubMed ID: 19091002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring micellar-based polymeric systems for effective nose-to-brain drug delivery as potential neurotherapeutics.
    Pokharkar V; Suryawanshi S; Dhapte-Pawar V
    Drug Deliv Transl Res; 2020 Aug; 10(4):1019-1031. PubMed ID: 31858442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress in nanoparticulate-based intranasal delivery for treating of different central nervous system diseases.
    Bseiso EA; Sheta NM; Abdel-Haleem KM
    Pharm Dev Technol; 2024 Oct; ():1-17. PubMed ID: 39340392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.